 "bayer")
Bayer launched a novel heart failure drug in India that it has co-developed with Merck at one-fifteenth of the global price at Rs 127 per pill. It’s a one pill a day therapy.
The drug named Verquvo (vericiguat) is the first novel treatment approved to reduce the risk of cardiovascular deaths and repeated hospitalisation among worsening heart failure patients, the company said.
In India there are between 8-10 million people with heart failure, making it one of the world's largest populations with the malady. At 55-60 years, Indian patients are also a decade younger than their western counterparts. Despite the
